Pulmonary Hypertension

HomePatientsLung Disease Week at the ATS2014 ▶ Pulmonary Hypertension
Pulmonary Hypertension Week

Pulmonary Hypertension Week

Welcome to the Pulmonary Hypertension Week at the ATS!

I would like to thank you for visiting us during Pulmonary Hypertension Week for the American Thoracic Society.  It is with great pleasure that we use this week to introduce pulmonary hypertension to a wide-reaching audience and explain our current knowledge and future perspectives in this disease.  The ATS has been instrumental in supporting ongoing research, through the Pulmonary Circulation Assembly, by promoting advancements in our understanding of cellular and molecular mechanisms of pulmonary vascular function, gas exchange and right heart dysfunction while encouraging new and innovative clinical trials, drug development, diagnostic and therapeutic interventions in pulmonary vascular disease.  The Pulmonary Hypertension Association is another great resource with abundant information, educational programs, support groups and resources for patients, families and medical practitioners regarding pulmonary hypertension.

Pulmonary hypertension represents a chronic, progressive condition characterized by elevated blood pressure in the circulation of the lung.  Patients often experience tiredness, shortness of breath, chest pain, fainting, and swelling of the legs and abdomen.  This condition often complicates many common diseases such as congestive heart failure, autoimmune diseases, sickle cell anemia, chronic obstructive pulmonary disease or blood clots in the pulmonary circulation.  The presence of pulmonary hypertension dramatically increases the risk of death in these conditions.  Our improved understanding and recognition of pulmonary hypertension has uncovered the impressive burden of this disease on our healthcare system.  The most recent estimates indicate that pulmonary hypertension is responsible for 260,000 hospital visits and over 15,000 deaths per year.  We hope that Pulmonary Hypertension Week for the American Thoracic Society will continue to increase the public recognition of this devastating disease which will continue to advance ongoing research and drug development.

Jason X.J. Yuan, MD, PhD

Jason X.J. Yuan, MD, PhD
Chair, ATS Pulmonary Circulation Cmte
American Thoracic Society
Member, ATS Board of Directors

Debbie Castro

Debbie Castro
Senior Director, Volunteer Services
Pulmonary Hypertension Association
Chair-elect, ATS Public Advisory Roundtable



The mission of the Pulmonary Hypertension Association (PHA) is to find ways to prevent and cure pulmonary hypertension, and to provide hope for the pulmonary hypertension community through support, education, advocacy and awareness.

The PHA is a young organization, changing the history of an illness. From simple beginnings — four women around a kitchen table in Florida in 1990 — PHA has evolved in size and complexity. Membership now includes over 13,000 patients and family members as well as two medical membership sections, one for physicians and researchers, the other for allied health professionals. The synergy created from the partnership of these constituencies has resulted in a community of hope and effective change.